GALE 301

Drug Profile

GALE 301

Alternative Names: E39 peptide vaccine; E39+GM-CSF vaccine; FBP-E39; Folate Binding Protein-E39 vaccine; GALE-301

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; University of Texas M. D. Anderson Cancer Center
  • Developer Galena Biopharma; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Peptide vaccines; Peptides; Protein-vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Endometrial cancer; Ovarian cancer
  • Phase I/II Breast cancer

Most Recent Events

  • 17 Mar 2017 Final adverse events data from a phase I/IIa trial in Ovarian and Endometrial cancer released by Galena Biopharma
  • 09 Mar 2017 COL George Peoples and M.D. Anderson Cancer Center completes a phase Ib/II trial in Breast cancer and Ovarian cancer (Prevention of relapse) in USA before March 2017 (NCT02019524)
  • 09 Mar 2017 COL George Peoples completes a phase Ib/IIa trial in Ovarian cancer and Endometrial cancer (Prevention of relapse; Adjuvant therapy) in USA (Intradermal) before March 2017 (NCT01580696)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top